companiesCompany
CanariaBio
aka OncoQuest, OncoQuest Pharmaceuticals, 카나리아바이오
CanariaBio is a South Korean biotech that took over oregovomab, an antibody against the ovarian cancer marker CA-125 that is given with chemotherapy to prime an immune response against the tumour.
Overview
CanariaBio acquired the oregovomab programme from OncoQuest of Edmonton, Canada. Oregovomab (MAb-B43.13) binds circulating CA-125 and, given at the same time as carboplatin and paclitaxel, forms immune complexes that induce CA-125-specific T-cell responses. After a phase 2 trial suggested longer progression-free survival, the phase 3 FLORA-5 trial in newly diagnosed advanced ovarian cancer read out in 2024 without meeting its primary endpoint.
Headquarters
Seongnam, KR
Scorecard
All companies#276of 1181 companies, score 13
- phase 3 +3
- modalities +2
- registry trials +8
0 approved, 1 in phase 3, 0 earlier, 0 targets, 15 registry studies. Formula on the scorecards page.
Type
biotech